NASDAQ:ARTL Artelo Biosciences Q1 2026 Earnings Report $2.68 -0.10 (-3.60%) Closing price 05/7/2026 04:00 PM EasternExtended Trading$2.70 +0.02 (+0.75%) As of 05/7/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Artelo Biosciences EPS ResultsActual EPSN/AConsensus EPS -$0.78Beat/MissN/AOne Year Ago EPSN/AArtelo Biosciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AArtelo Biosciences Announcement DetailsQuarterQ1 2026Date5/19/2026TimeBefore Market OpensConference Call DateWednesday, May 13, 2026Conference Call Time9:30AM ETConference Call ResourcesEarnings HistoryCompany Profile Artelo Biosciences Earnings HeadlinesArtelo Biosciences Announces Strategic Collaboration with Artificial Intelligence (AI) Leader ScienceMachine Highlighting New Expansion Opportunities and Insights for FABP5 ...April 28, 2026 | markets.businessinsider.comArtelo Biosciences Partners with ScienceMachine to Enhance FABP5 Inhibitor Development Through AI TechnologyApril 28, 2026 | quiverquant.comQYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today. | Profits Run (Ad)Artelo Biosciences Announces Strategic Collaboration with Artificial Intelligence (AI) Leader ScienceMachine Highlighting New Expansion Opportunities and Insights for FABP5 Inhibitor DevelopmentApril 28, 2026 | globenewswire.comWhat's behind the rise in Artelo Biosciences stock?April 21, 2026 | msn.comWhat's Behind The Rise In Artelo Biosciences Stock?April 20, 2026 | benzinga.comSee More Artelo Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Artelo Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Artelo Biosciences and other key companies, straight to your email. Email Address About Artelo BiosciencesArtelo Biosciences (NASDAQ:ARTL) is a clinical-stage biopharmaceutical company focused on the development of novel small-molecule therapies for pain, inflammation, ocular and cardiometabolic disorders. The company leverages a proprietary drug delivery and targeting platform designed to enhance the safety and efficacy profiles of well-characterized active pharmaceutical ingredients. Artelo’s approach is centered on repurposing and optimizing therapeutic molecules to address significant unmet medical needs, with particular emphasis on improving patient tolerability and clinical outcomes. The company’s lead program, AB101, is an orally bioavailable ion channel modulator in development for neuropathic pain conditions including post-herpetic neuralgia. In parallel, Artelo is advancing AB188, a topical formulation aimed at treating ocular surface diseases such as dry eye syndrome. Earlier-stage preclinical candidates are being explored for inflammatory and cardiometabolic indications, reflecting the versatility of Artelo’s platform technology in shaping molecular properties to target diverse disease pathways. Founded as a Delaware corporation, Artelo Biosciences is headquartered in Cleveland, Ohio, and conducts research and development activities in the United States. The executive leadership team brings together expertise in medicinal chemistry, pharmaceutical development and regulatory strategy. Artelo continues to engage with key opinion leaders and strategic partners to support its pipeline through proof-of-concept studies and toward eventual regulatory filings.View Artelo Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles The AI Fear Around Datadog Stock May Have Been Completely WrongAmprius Technologies Ups the Voltage on Forward OutlookWhy Lam Research Still Looks Like a Buy After a 300% RallyIonQ Just Posted a Breakout Quarter—But 1 Problem RemainsSuper Micro Surges Over 20% as Margins Soar, Sales Fall ShortNuts and Bolts AI Play Gains Momentum: Astera Labs Targets RaisedAnheuser-Busch Stock Jumps as Volume Growth Signals Turnaround Upcoming Earnings Brookfield Asset Management (5/8/2026)Enbridge (5/8/2026)Toyota Motor (5/8/2026)Ubiquiti (5/8/2026)Constellation Energy (5/11/2026)Barrick Mining (5/11/2026)Petroleo Brasileiro S.A.- Petrobras (5/11/2026)Simon Property Group (5/11/2026)SEA (5/12/2026)Cisco Systems (5/13/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
